RespiDART 2022: Frontiers in Drug Development against Respiratory Viruses

RespiDART 2022：抗呼吸道病毒药物开发的前沿

• 批准号: 10609297
• 负责人: Asuncion Mejias
• 金额: $ 0.65万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-12-01 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10609297
• 关键词: 2019-nCoV; Accreditation; Address; Adult; Antiviral Agents; Antiviral Therapy; Area; Biological Assay; Biology; COVID-19; COVID-19 pandemic; Chemistry; Childhood; Clinical; Clinical Research; Communities; Coronavirus; Data; Developing Countries; Development; Diagnosis; Drug resistance; Education; Educational workshop; Elderly; Environment; Enzymatic Biochemistry; Epidemiology; Evolution; Future; Goals; HIV; Health; Health Personnel; Hepatitis B; Hepatitis C; Human; Immunocompromised Host; Immunology; Infant; International; Knowledge; Location; Long COVID; Measures; Medical; Metapneumovirus; Methods; Mexican; Mexico; Oral; Participant; Pharmacology; Population; Postdoctoral Fellow; Program Effectiveness; Public Health; Resistance; Respiratory Disease; SARS-CoV-2 variant; Safety; Scholarship; Scientist; Series; Services; Socialization; Special Population; Surveys; Therapeutic; Training; Travel; Vaccination; Vaccines; Viral; Virus; Virus Diseases; Virus Replication; Vulnerable Populations; animal model development; barrier to care; co-infection; coronavirus pandemic; cross disciplinary program; design; drug development; drug discovery; effectiveness evaluation; frontier; global health; graduate student; influenzavirus; lectures; meetings; novel; novel therapeutics; pandemic disease; parainfluenza virus; peer; posters; programs; research and development; research clinical testing; respiratory virus; screening; small molecule; sobriety; symposium; therapeutic development; therapy development; tool; vaccine development; virtual; virus host interaction

Abstract/ Project Summary Since 1995, the DART conference series have focused on the latest developments in antiviral therapy against viruses such as HIV, hepatitis B and hepatitis C. Just as viruses are ever evolving, the DART series strives to adapt itself to emerging challenges facing today’s global community. Respiratory viruses such as RSV and influenza virus have longed threatened human health, especially in vulnerable populations such as infants, the elderly, and the immunocompromised. The recent coronavirus pandemic has shaken the world to its core and has served as a sobering reminder of the importance of continued research and development in this arena. By bringing together world leaders and key opinion holders, RespiDART 2022 will tackle challenges in drug discovery/development and vaccines against respiratory viruses. The specific aims are: 1. To provide an interactive workshop setting where clinicians, scientists and health care workers can share and discuss the latest medical and scientific developments in the field of therapeutics development against respiratory viruses; 2. Develop a cross-disciplinary program that facilitates the neutral and balanced exchange of scientific knowledge in the areas of biology, chemistry, pharmacology, clinical research and public health as related to topics such as epidemiology and barriers to treatment, vaccine development, and recent clinical advances of small molecules; 3. Enhance the training of young scientists and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships in a CME accredited setting. The educational objectives are: 1. Epidemiology, screening, and diagnosis of respiratory viruses with a special focus on SARS-CoV-2. 2. Drug discovery and development. 3. Clinical evaluation of novel therapeutics in development against respiratory viruses such as SARS-CoV-2. influenza virus, RSV, parainfluenza virus, and metapneumovirus. 4. Long COVID-19. 5. Respiratory virus enzymology, host-virus interactions and virus replication. 6. Immunology and vaccine development. 7. Impact of SARS-CoV-2 variant emergence on therapeutics, vaccines and epidemiology. 8. Novel assay and animal model development. 9. Drug resistance, vaccine resistance, and viral evolution. 10. SARS-CoV-2 and other viral infections and respiratory diseases in adults and pediatric populations, including SARS-CoV-2/viral coinfections. Design & Methods: RespiDART 2022 will take place in Los Cabos, Mexico over a two-day period, at a location that is easily accessed by both national and international delegates. Mexican doctors (including those servicing the local population) as well as numerous scientists from underdeveloped countries will be invited to attend. The program will include lectures, oral abstract presentations, discussion panels and a poster session. Virtual participation option will be set up in case the ongoing pandemic makes it unsafe to travel to the conference. We believe that RespiDART 2022 is a much needed and timely platform for the discussion of the latest developments in this fast-evolving area of global health.

摘要/项目摘要 自1995年以来，DART会议系列一直专注于抗病毒治疗的最新发展。 艾滋病毒、乙肝和丙型肝炎等病毒，就像病毒不断进化一样，DART系列努力 使自己适应当今全球社会面临的新挑战。呼吸道病毒，如呼吸道合胞病毒和 流感病毒长期以来一直威胁着人类的健康，特别是在婴儿等脆弱人群中， 老年人，免疫功能受损。最近的冠状病毒大流行震撼了世界的核心和 已经清醒地提醒人们，在这个领域继续研究和开发的重要性。 通过汇聚世界领导人和关键意见持有者，RespiDART 2022将应对毒品领域的挑战 发现/开发和预防呼吸道病毒的疫苗。具体目标是：1.提供一个 互动工作坊环境，临床医生、科学家和医护人员可以分享和讨论 针对呼吸道病毒的治疗开发领域的最新医学和科学发展； 2.制定跨学科计划，促进中立和平衡的科学交流 在生物、化学、药理学、临床研究和公共卫生等领域的知识 诸如流行病学和治疗障碍、疫苗开发和最近的临床进展 小分子；3.加强对青年科学家的培训，为 通过参加CME认证的奖学金，代表不足的科学家和卫生保健工作者 布景。教育目标是：1.呼吸道病毒的流行病学、筛查和诊断 特别关注SARS-CoV-2。2.药物发现和开发。3.新药的临床评价 针对SARS-CoV-2等呼吸道病毒的治疗药物正在开发中。流感病毒，呼吸道合胞病毒， 副流感病毒和偏肺炎病毒。4.新冠肺炎。5.呼吸道病毒酶学、宿主病毒 相互作用和病毒复制。6.免疫学和疫苗开发。7.SARS-CoV-2变种的影响 出现在治疗学、疫苗和流行病学方面。8.新的检测方法和动物模型的建立。9. 抗药性、疫苗抗药性和病毒进化。10.SARS-CoV-2和其他病毒感染和 成人和儿科人群中的呼吸道疾病，包括SARS-CoV-2/病毒混合感染。设计与 方法：RespiDART 2022将在墨西哥洛斯卡波斯举行，为期两天，地点是 各国代表和国际代表都可以轻松访问。墨西哥医生(包括为 来自不发达国家的许多科学家将应邀参加。这个 课程将包括讲座、口头摘要报告、讨论小组和海报会议。虚拟 将设置参与选项，以防正在进行的大流行使前往会议变得不安全。 我们认为，RespiDART 2022是一个非常需要和及时的平台，可以讨论最新的 这一快速发展的全球卫生领域的发展。